Effects of modulating in vivo nitric oxide production on the incidence and severity of PDE4 inhibitor-induced vascular injury in sprague-dawley rats

Toxicological Sciences

Volumn 122, Issue 1, 2011, Pages 7-15

  Sheth, Christopher M ^a,c   Enerson, Bradley E ^b   Peters, David ^a   Lawton, Michael P ^b   Weaver, James L ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b PFIZER INC   (United States)

^c U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

Author keywords

Drug induced vascular injury; Mesenteric artery; Nitric oxide; Nitrotyrosine; PDE4 inhibitor; Serum nitrite

Indexed keywords

3 NITROTYROSINE; CI 1044; LINSIDOMINE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRITE; PHOSPHODIESTERASE IV INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOSYNTHESIS; BLOOD LEVEL; BLOOD VESSEL INJURY; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INCIDENCE; MALE; MESENTERIC ARTERY; NONHUMAN; PATHOGENESIS; RAT; REGULATORY MECHANISM; SPRAGUE DAWLEY RAT;

RATTUS;

EID: 79960986630     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfr082     Document Type: Article

References (41)

1. Albassam, M. A., Metz, A. L., Potoczak, R. E., Gallagher, K. P., Haleen, S., Hallak, H., and McGuire, E. J. (2001). Studies on coronary arteriopathy in dogs following administration of CI-1020, an endothelin A receptor antagonist. Toxicol. Pathol. 29, 277-284.
2. Burnouf, C., Auclair, E., Avenel, N., Bertin, B., Bigot, C., Calvet, A., Chan, K., Durand, C., Fasquelle, V., Feru, F., et al. (2000). Synthesis, structure-activity relationships, and pharmacological profile of 9-amino-4-oxo-1-phenyl-3,4,6,7-tetrahydro[1,4]diazepino[6,7,1-hi]indoles: discovery of potent, selective phosphodiesterase type 4 inhibitors. J. Med. Chem. 43, 4850-4867.
3. Butler, A. R., Megson, I. L., and Wright, P. G. (1998). Diffusion of nitric oxide and scavenging by blood in the vasculature. Biochim. Biophys. Acta 1425, 168-176.
4. 1 mice. Fundam. Appl. Toxicol. 11, 472-484.
5. Crow, J. P., and Beckman, J. S. (1995). Reactions between nitric oxide, superoxide, and peroxynitrite: footprints of peroxynitrite in vivo. Adv. Pharmacol. 34, 17-43.
6. Dagues, N., Pawlowski, V., Sobry, C., Hanton, G., Borde, F., Soler, S., Freslon, J. L., and Chevalier, S. (2007). Investigation of the molecular mechanisms preceding PDE4 inhibitor-induced vasculopathy in rats: tissue inhibitor of metalloproteinase 1, a potential predictive biomarker. Toxicol. Sci. 100, 238-247.
7. Dalmas, D. A., Scicchitano, M. S., Chen, Y., Kane, J., Mirabile, R., Schwartz, L. W., Thomas, H. C., and Boyce, R. W. (2008). Transcriptional profiling of laser capture microdissected rat arterial elements: fenoldopaminduced vascular toxicity as a model system. Toxicol. Pathol. 36, 496-519.
8. Denicola, A., and Radi, R. (2005). Peroxynitrite and drug-dependent toxicity. Toxicology 208, 273-288.
9. Dimmeler, S., and Zeiher, A. M. (1997). Nitric oxide and apoptosis: another paradigm for the double-edged role of nitric oxide. Nitric Oxide 1, 275-281.
10. Eckly, A. E., and Lugnier, C. (1994). Role of phosphodiesterases III and IV in the modulation of vascular cyclic AMP content by the NO/cyclic GMP pathway. Br. J. Pharmacol. 113, 445-450.
11. Enerson, B. E., Lin, A., Lu, B., Zhao, H., Lawton, M. P., and Floyd, E. (2006). Acute drug-induced vascular injury in beagle dogs: pathology and correlating genomic expression. Toxicol. Pathol. 34, 27-32.
12. Fortin, C. F., McDonald, P. P., Fulop, T., and Lesur, O. (2010). Sepsis, leukocytes, and nitric oxide (NO): an intricate affair. Shock 33, 344-352.
13. Hakim, T. S., Sugimori, K., Camporesi, E. M., and Anderson, G. (1996). Half-life of nitric oxide in aqueous solutions with and without haemoglobin. Physiol. Meas. 17, 267-277.
14. Hanton, G., Sobry, C., Dagues, N., Provost, J. P., Le Net, J. L., Comby, P., and Chevalier, S. (2008). Characterisation of the vascular and inflammatory lesions induced by the PDE4 inhibitor CI-1044 in the dog. Toxicol. Lett. 179, 15-22.
15. Hashimoto, A., Miyakoda, G., Hirose, Y., and Mori, T. (2006). Activation of endothelial nitric oxide synthase by cilostazol via a protein kinase A- and phosphatidylinositol 3-kinase/Akt-dependent mechanism. Atherosclerosis 189, 350-357.
16. Heaslip, R. J., Lombardo, L. J., Golankiewicz, J. M., Ilsemann, B. A., Evans, D. Y., Sickels, B. D., Mudrick, J. K., Bagli, J., and Weichman, B. M. (1994). Phosphodiesterase-IV inhibition, respiratory muscle relaxation and bronchodilation by WAY-PDA-641. J. Pharmacol. Exp. Ther. 268, 888-896.
17. Heijnen, H. F. G., Waaijenborg, S., Crapo, J. D., Bowler, R. P., Akkerman, J. W. N., and Slot, J. W. (2004). Colocalization of eNOS and the catalytic subunit of PKA in endothelial cell junctions: a clue for regulated NO production. J. Histochem. Cytochem. 52, 1277-1285.
18. Kelm, M., Preik-Steinhoff, H., Preik, M., and Strauer, B. E. (1999). Serum nitrite sensitively reflects endothelial NO formation in human forearm vasculature: evidence for biochemical assessment of the endothelial L-arginine-NO pathway. Cardiovasc. Res. 41, 765-772.
19. Kerns, W., Schwartz, L., Blanchard, K., Burchiel, S., Essayan, D., Fung, E., Johnson, R., Lawton, M., Louden, C., MacGregor, J., et al. (2005). Druginduced vascular injury-a quest for biomarkers. Toxicol. Appl. Pharmacol. 203, 62-87.
20. Korkmaz, S., Maupoil, V., Sobry, C., Brunet, C., Chevalier, S., and Freslon, J. L. (2009). An increased regional blood flow precedes mesenteric inflammation in rats treated by a phosphodiesterase 4 inhibitor. Toxicol. Sci. 107, 298-305.
21. Kruskal, W. H., and Wallis, W. A. (1952). Use of ranks in one-criterion variance analysis. J. Am. Stat. Assoc. 47, 583-621.
22. Liu, D., Homan, L. L., and Dillon, J. S. (2004). Genistein acutely stimulates nitric oxide synthesis in vascular endothelium cells by a cyclic adenosine 5'-monophosphate-dependent mechanism. Endocrinology 145, 5532-5539.
23. Losco, P. E., Evans, E. W., Barat, S. A., Blackshear, P. E., Reyderman, L., Fine, J. S., Bober, L. A., Anthes, J. C., Mirro, E. J., and Cuss, F. M. (2004). The toxicity of SCH 351591, a novel phosphodiesterase-4 inhibitor, in Cynomolgus monkeys. Toxicol. Pathol. 32, 295-308.
24. Pacher, P., Beckman, J. S., and Liaudet, L. (2007). Nitric oxide and peroxynitrite in health and disease. Physiol. Rev. 87, 315-424.
25. Pacher, P., and Szabo, C. (2006). Role of peroxynitrite in the pathogenesis of cardiovascular complications of diabetes. Curr. Opin. Pharmacol. 6, 136-141.
26. Papapetropoulos, A., Rudic, R. D., and Sessa, W. C. (1999). Molecular control of nitric oxide synthases in the cardiovascular system. Cardiovasc. Res. 43, 509-520.
27. Polson, J. B., and Strada, S. J. (1996). Cyclic nucleotide phosphodiesterases and vascular smooth muscle. Annu. Rev. Pharmacol. Toxicol. 36, 403-427.
28. Raghavan, S. A. V., and Dikshit, M. (2004). Vascular regulation by the L-arginine metabolites, nitric oxide and agmatine. Pharmacol. Res. 49, 397-414.
29. Sessa, W. C. (2004). eNOS at a glance. J. Cell Sci. 117, 2427-2429.
30. Slim, R. M., Song, Y., Albassam, M., and Dethloff, L. A. (2003). Apoptosis and nitrative stress associated with phosphodiesterase inhibitor-induced mesenteric vasculitis in rats. Toxicol. Pathol. 31, 638-645.
31. Thomas, D. D., Ridnour, L.A., Isenberg, J. S., Flores-Santana,W., Switzer, C. H., Donzelli, S., Hussain, P., Vecoli, C., Paolocci, N., Ambs, S., et al. (2008). The chemical biology of nitric oxide: implications in cellular signaling. Free Radic. Biol. Med. 45, 18-31.
32. van Vleet, J. F., Herman, E. H., and Ferrans, V. J. (1984). Cardiac morphologic alterations in acute minoxidil cardiotoxicity in miniature swine. Exp. Mol. Pathol. 41, 10-25.
33. Weaver, J. L., Snyder, R., Knapton, A., Herman, E. H., Honchel, R., Miller, T., Espandiari, P., Smith, R., Gu, Y. Z., Goodsaid, F. M., et al. (2008). Biomarkers in peripheral blood associated with vascular injury in Sprague-Dawley rats treated with the phosphodiesterase IV inhibitors SCH 351591 or SCH 534385. Toxicol. Pathol. 36, 840-849.
34. Weaver, J. L., Zhang, J., Knapton, A., Miller, T. E., Espandiari, P., Smith, R., Gu, Y.-Z., and Snyder, R. (2010). Early events in vascular injury in the rat induced by the phosphodiesterase IV inhibitor SCH 351591. Toxicol. Pathol. 38, 738-744.
35. Wilcoxon, F., and Wilcox, R. A. (1964). Some Rapid Approximate Statistical Procedures. Lederle Laboratories, Pearl River, NY.
36. Wink, D. A., Hanbauer, I., Krishna, M. C., DeGraff, W., Gamson, J., and Mitchell, J. B. (1993). Nitric oxide protects against cellular damage and cytotoxicity from reactive oxygen species. Proc. Natl. Acad. Sci. U.S.A. 90, 9813-9817.
37. Wink, D. A., Kasprzak, K. S., Maragos, C. M., Elespuru, R. K., Misra, M., Dunams, T. M., Cebula, T. A., Koch, W. H., Andrews, A. W., Allen, J. S., et al. (1991). DNA deaminating ability and genotoxicity of nitric oxide and its progenitors. Science 254, 1001-1003.
38. Zhang, J., Herman, E. H., Knapton, A., Chadwick, D. P.,Whitehurst, V. E., Koerner, J. E., Papoian, T., Ferrans, V. J., and Sistare, F. D. (2002). SK&F 95654-induced acute cardiovascular toxicity in Sprague-Dawley rats-histopathologic, electron microscopic, and immunohistochemical studies. Toxicol. Pathol. 30, 28-40.
39. Zhang, J., Herman, E. H., Robertson, D. G., Reily, M. D., Knapton, A., Ratajczak, H. V., Rifai, N., Honchel, R., Blanchard, K. T., Stoll, R. E., et al. (2006). Mechanisms and biomarkers of cardiovascular injury induced by phosphodiesterase inhibitor III SK&F 95654 in the spontaneously hypertensive rat. Toxicol. Pathol. 34, 152-163.
40. Zhang, J., Snyder, R. D., Herman, E. H., Knapton, A., Honchel, R., Miller, T., Espandiari, P., Goodsaid, F. M., Rosenblum, I. Y., Hanig, J. P., et al. (2008). Histopathology of vascular injury in Sprague-Dawley rats treated with phosphodiesterase IV inhibitor SCH 351591 or SCH 534385. Toxicol. Pathol. 36, 827-839.
41. Zhang, X. P., and Hintze, T. H. (2006). cAMP signal transduction induces eNOS activation by promoting PKB phosphorylation. Am. J. Physiol. Heart Circ. Physiol. 290, H2376-H2384.